CA
NZ
UK
AU
IND
US
● Vor Bio released a post hoc analysis of Phase 3 telitacicept data in generalized myasthenia gravis on September 29, 2026.
● JPMorgan initiated coverage of AbCellera with an Overweight rating and a $17 price target on Tuesday, September 29, 2026.
● The FDA issued warning letters to Neogen and contract manufacturer Sciarra Aeromed on Tuesday, September 29, 2026.
● Stifel upgraded STAAR Surgical to Buy from Hold on September 29, 2026, and raised its target to $31 from $28.
● Iovance raised 2026Revenueguidance to $410 million to $420 million from $350 million to $370 million.
● Iovance raised 2026Revenueguidance to $410 million to $420 million on strong U.S.Demandfor its cancer treatments.
● Interim CEO Frederick Vogt said increasing patientDemandand the currentManufacturingschedule provide strong visibility.
● uniQure released 48-month AMT-130 data on September 29, 2026; shares traded near $25.32 at midday after a steeper premarket drop.
● uniQure traded near $25.32 at midday on Tuesday, September 29, 2026, after an even deeper drop in premarket trading.
● CEO Matt Kapusta said the comparator increasingly reflected a healthier population than at baseline, a bias that cuts against AMT-130.
Please wait processing your request...